Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of <i>Lactococcus lactis</i> against divergent influenza viruses in mice

Han, Lei; Gao, Tong; Cen, Qianhong

doi:10.1080/21505594.2020.1857162

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HA stalk has a lower mutability compared to the HA globular head. Abs directed against the HA stalk domain are found to be capable of neutralizing heterologous influenza viruses, due to the relative conservation of the HA stalk across divergent subtypes of influenza [ 42 ]. However, the proximal stalk domain along with conserved parts of the head domain of HA is immunosubdominant [ 43 ].…”

Section: Human Universal Flu Vaccinementioning

confidence: 99%

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Lim,

Komarasamy,

Adnan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

Every year, influenza virus infections cause significant morbidity and mortality worldwide. They pose a substantial burden of disease, in terms of not only health but also the economy. Owing to the ability of influenza viruses to continuously evolve, annual seasonal influenza vaccines are necessary as a prophylaxis. However, current influenza vaccines against seasonal strains have limited effectiveness and require yearly reformulation due to the virus undergoing antigenic drift or shift. Vaccine mismatches are common, conferring suboptimal protection against seasonal outbreaks, and the threat of the next pandemic continues to loom. Therefore, there is a great need to develop a universal influenza vaccine (UIV) capable of providing broad and durable protection against all influenza virus strains. In the quest to develop a UIV that would obviate the need for annual vaccination and formulation, a multitude of strategies is currently underway. Promising approaches include targeting the highly conserved epitopes of haemagglutinin (HA), neuraminidase (NA), M2 extracellular domain (M2e) and internal proteins of the influenza virus. The identification and characterization of broadly neutralizing antibodies (bnAbs) targeting conserved regions of the viral HA protein, in particular, have provided important insight into novel vaccine designs and platforms. This review discusses universal vaccine approaches presently under development, with an emphasis on those targeting the highly conserved stalk of the HA protein, recent technological advancements used and the future prospects of a UIV in terms of its advantages, developmental obstacles and potential shortcomings.

show abstract

Section: Human Universal Flu Vaccinementioning

confidence: 99%

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Lim,

Komarasamy,

Adnan

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…An essential advantage of oral vaccines is their stability, simplifying logistics and storage conditions [ 40 , 41 ]. Oral vaccine approaches to treat influenza, dengue, tetanus, diphtheria, and MERS-CoV have been published [ 42 – 46 ]. Until now, oral administration requires more studies for its approval because it usually presents a suboptimal induction of cellular immune responses and neutralizing antibodies.…”

Section: Introductionmentioning

confidence: 99%

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Valdez‑Cruz,

Rosiles-Becerril,

Martínez-Olivares

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

Background Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently presented for generating neutralizing antibodies and as a model for new vaccines. Results This work presents the development of an applicable technology through the oral administration of the SARS-CoV-2 RBD antigen fused with a peptide to improve its antigenic presentation. We focused on the development and production of the recombinant receptor binding domain (RBD) produced in E. coli modified with the addition of amino acids extension designed to improve antigen presentation. The production was carried out in shake flask and bioreactor cultures, obtaining around 200 mg/L of the antigen. The peptide-fused RBD and peptide-free RBD proteins were characterized and compared using SDS-PAGE gel, high-performance chromatography, and circular dichroism. The peptide-fused RBD was formulated in an oil-in-water emulsion for oral mice immunization. The peptide-fused RBD, compared to RBD, induced robust IgG production in mice, capable of recognizing the recombinant RBD in Enzyme-linked immunosorbent assays. In addition, the peptide-fused RBD generated neutralizing antibodies in the sera of the dosed mice. The formulation showed no reactive episodes and no changes in temperature or vomiting. Conclusions Our study demonstrated the effectiveness of the designed peptide added to the RBD to improve antigen immunostimulation by oral administration. Graphical Abstract

show abstract

“…At present, the most used immunogen for AIV subunit vaccines is hemagglutinin (HA), the main trimeric glycoprotein on the surface of the influenza virus. Using different expression systems, many studies have demonstrated that the HA subunit vaccine possesses the potential to be a candidate vaccine [ 15 , 16 , 17 , 18 , 19 ]. However, the successful development of a commercial subunit vaccine remains challenging.…”

Section: Introductionmentioning

confidence: 99%

Influenza H7N9 Virus Hemagglutinin with T169A Mutation Possesses Enhanced Thermostability and Provides Effective Immune Protection against Lethal H7N9 Virus Challenge in Chickens

Chen

Kong

et al. 2023

Vaccines

View full text Add to dashboard Cite

H7N9 avian influenza virus (AIV) has caused huge losses in the poultry industry and impacted human public health security, and still poses a potential threat. Currently, immune prevention and control of avian influenza relies on traditional inactivated vaccines; however, they have some limitations and genetically engineered avian influenza subunit vaccines may be potential candidate vaccines. In this study, a T169A mutation in the HA protein derived from H7N9 AIV A/Chicken/Guangdong/16876 (H7N9-16876) was generated using the baculovirus expression system (BVES). The results showed that the mutant (HAm) had significantly increased thermostability compared with the wild-type HA protein (HA-WT). Importantly, immunizing chickens with HAm combined with ISA 71VG elicited higher cross-reactive hemagglutination inhibition (HI) antibody responses and cytokine (IFN-γ and IL-4) secretion. After a lethal challenge with heterologous H7N9 AIV, the vaccine conferred chickens with 100% (10/10) clinical protection and effectively inhibited viral shedding, with 90% (9/10) of the chickens showing no virus shedding. The thermostability of HAm may represent an advantage in practical vaccine manufacture and application. In general, the HAm generated in this study represents a promising subunit vaccine candidate for the prevention and control of H7N9 avian influenza.

show abstract

Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of Lactococcus lactis against divergent influenza viruses in mice

Cited by 7 publications

References 29 publications

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Influenza H7N9 Virus Hemagglutinin with T169A Mutation Possesses Enhanced Thermostability and Provides Effective Immune Protection against Lethal H7N9 Virus Challenge in Chickens

Contact Info

Product

Resources

About